1. Mead GM. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clinical Oncol 1997;15(2):594-603. DOI: 10.1200/JCO.1997.15.2.594
2. Williams S.D., Birch R., Einhorn L.H. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316(23):1435-1440. DOI: 10.1056/NEJM198706043162302
3. Gillessen S., Sauvé N., Collette L. et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol 2021;39(14):1563-1574. DOI: 10.1200/JCO.20.03296 EDN: ZHHFZI
4. Nichols C.R., Catalano P.J., Crawford E.D. et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16(4):1287-1293. DOI: 10.1200/JCO.1998.16.4.1287
5. Christian J.A., Huddart R.A., Norman A. et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003;21(5):871-877. DOI: 10.1200/JCO.2003.05.155
6. Feldman D.R., Hu J., Srinivas S. et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediateor poor-risk germ cell tumors (GCT). J Clin Oncol 2018;36(15_suppl):4508-4508. DOI: 10.1200/JCO.2018.36.15_suppl.4508
7. Bokemeyer C., Kollmannsberger C., Meisner C. et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999;17(11):3450-3456. DOI: 10.1200/JCO.1999.17.11.345
8. Droz J.P., Kramar A., Biron P. et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007;51(3):739-748. DOI: 10.1016/J.EURURO.2006.10.03
9. Necchi A., Mariani L., Di Nicola M. et al. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italianrandomized phase II study. Ann Oncol 2015;26(1):167-172. DOI: 10.1093/annonc/mdu485 EDN: YGNUEF
10. Tryakin A., Fedyanin M., Kanagavel D. et al. Paclitaxel + BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: A phase II study. Urology 2011;78(3):620-625. 10. DOI: 10.1016/j.urology.2011.05.005 EDN: PDZESJ
11. Grimison P.S., Stockler M.R., Chatfield M. et al. Accelerated BEP for metastatic germ cell tumours: A multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Ann Oncol 2014;25(1):143-148. DOI: 10.1093/annonc/mdt369 EDN: UUGVEN
12. Fizazi K., Culine S., Kramar A. et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004;22(19):3868-3876. DOI: 10.1200/JCO.2004.04.008
13. Fizazi K., Pagliaro L., Laplanche A. et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014;15(13):1442-1450. DOI: 10.1016/S1470-2045(14)70490-5 EDN: UPOAHN
14. Oldenburg J., Berney D.M., Bokemeyer C. et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33(4):362-375. DOI: 10.1016/j.annonc.2022.01.002 EDN: VYBACJ
15. Матвеев В.Б., Волкова М.И., Гладков О.А. и соавт. Герминогенные опухоли у мужчин. Практические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли 2024;14(3s2):267-299. DOI: 10.18027/2224-5057-2024-14-3s2-1.2-11
16. Fizazi K., Le Teuff G., Fléchon A. et al. Personalized chemotherapy on the basis of tumor marker decline in poor-prognosis germ-cell tumors: updated analysis of the GETUG-13 phase III trial. J Clin Oncol 2024;42(28):3270-3276. DOI: 10.1200/JCO.23.01960 EDN: KOQGEP
17. Mego M., Rejlekova K., Svetlovska D. et al. Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial. Eur Urol Open Sci 2021;33:19-27. DOI: 10.1016/J.EUROS.2021.09.002
18. Motzer R., Nichols C., Margolin K. et al. Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. J Clin Oncol 2007;25:247-256. DOI: 10.1200/JCO.2005.05.4528
19. Daugaard G., Skoneczna I., Aass N. et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011;22(5):1054-1061. DOI: 10.1093/annonc/mdq575
20. Loriot Y., Pagliaro L., Fléchon A. et al. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. Eur J Cancer 2017;87:140-146. DOI: 10.1016/j.ejca.2017.09.029 EDN: YKDGBC
21. Pitz M.W., Desai A., Grossman S.A., Blakeley J.O. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 2011;104(3):629-638. DOI: 10.1007/S11060-011-0564-y
22. Tryakin A., Fedyanin M., Bulanov A. et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol 2018;144(9):1817-1823. DOI: 10.1007/S00432-018-2695-4
23. Cafferty F.H., White J.D., Shamash J. et al. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604). Eur J Cancer 2020;127:139-149. DOI: 10.1016/j.ejca.2019.12.028 EDN: ANTHKM